Depletion of RECQL4 or BLM in human glioma cells by CRISPR/Cas9 editing resulted in profound changes in the transcriptome, reduction of glioma sphere formation and augmented vulnerability to chemotherapeutics [11, 12]. This evidence concerns the gene RECQL4 and central nervous system cancer.